Pharvaris
Emily Jochim is currently serving as the Vice President and Head of Clinical Development Operations at Pharvaris. Prior to their current role, Emily held positions at Takeda as the Senior Director of Clinical Operations for Rare Diseases, at Shire as the Director of Clinical Programs, as well as various roles at Momenta Pharmaceuticals and Boston Life Sciences Inc. Emily holds an MBA in Health Sector Management from Questrom School of Business at Boston University and a Bachelor of Arts degree from the University of Maryland.
This person is not in any offices
Pharvaris
2 followers
Pharvaris is a preclinical stage company focused on bringing an oral bradykinin B2 receptor antagonist to patients for use as an alternative to injected therapies for hereditary angioedema (HAE) and other B2 receptor-mediated indications. The company reunites the core team responsible for the discovery and approval of the HAE treatment icatibant. With novel small molecules, we have identified and are advancing potent, orally available compounds targeting this clinically proven therapeutic target.